The Asia Pacific Precision Diagnostics Market is projected to witness market growth of 18.7% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific Precision Diagnostics Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $3.64 billion by 2031. The Japan market is showcasing a CAGR of 18.1% during (2024 - 2031). Additionally, The India market would register a CAGR of 19.6% during (2024 - 2031).
Precision diagnostics are vital for rapidly and accurately detecting infectious agents, characterization of antimicrobial resistance, and epidemiological surveillance. PCR and sequencing-based tests for viral, bacterial, and fungal infections (e.g., COVID-19 diagnostics). Identifying genetic markers of resistance to guide antibiotic therapy.
Additionally, they assess genetic variants affecting drug metabolism and response (e.g., CYP2D6, CYP2C19), identify genetic predispositions to adverse drug reactions and drug-induced toxicities, and target cancer therapies based on tumor genetic profiling and drug sensitivity testing.
Diseases such as cancer, diabetes, respiratory illnesses, and cardiovascular conditions are prevalent in Australia's aging population, driving the need for precise and early diagnostics. According to the Government of Australia, among people of all ages, an estimated 15.4 million (61%) were living with at least one of the selected long-term health conditions in 2022. This ranged from 28% of people aged 0-14 to 94% aged 85 and over. Precision diagnostics are crucial in early disease detection, enabling timely interventions and personalized treatment plans tailored to individual patient profiles.
The China market dominated the Asia Pacific Precision Diagnostics Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $3.64 billion by 2031. The Japan market is showcasing a CAGR of 18.1% during (2024 - 2031). Additionally, The India market would register a CAGR of 19.6% during (2024 - 2031).
Precision diagnostics are vital for rapidly and accurately detecting infectious agents, characterization of antimicrobial resistance, and epidemiological surveillance. PCR and sequencing-based tests for viral, bacterial, and fungal infections (e.g., COVID-19 diagnostics). Identifying genetic markers of resistance to guide antibiotic therapy.
Additionally, they assess genetic variants affecting drug metabolism and response (e.g., CYP2D6, CYP2C19), identify genetic predispositions to adverse drug reactions and drug-induced toxicities, and target cancer therapies based on tumor genetic profiling and drug sensitivity testing.
Diseases such as cancer, diabetes, respiratory illnesses, and cardiovascular conditions are prevalent in Australia's aging population, driving the need for precise and early diagnostics. According to the Government of Australia, among people of all ages, an estimated 15.4 million (61%) were living with at least one of the selected long-term health conditions in 2022. This ranged from 28% of people aged 0-14 to 94% aged 85 and over. Precision diagnostics are crucial in early disease detection, enabling timely interventions and personalized treatment plans tailored to individual patient profiles.
List of Key Companies Profiled
- Abbott Laboratories
- F.Hoffmann-La Roche Ltd.
- Siemens Healthineers AG (Siemens AG)
- Thermo Fisher Scientific, Inc.
- Danaher Corporation
- Agilent Technologies, Inc.
- BioMerieux S.A.
- Becton, Dickinson and Company
- Qiagen N.V
- Hologic, Inc.
Market Report Segmentation
By End-use- Clinical Laboratories
- Hospitals
- Others
- Genetic Tests
- Esoteric Tests
- Direct to Consumer Tests
- Others
- Oncology
- Respiratory Diseases
- CNS Disorders
- Immunology
- Skin Diseases
- Genetic Diseases
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Asia Pacific Precision Diagnostics Market by End-use
Chapter 6. Asia Pacific Precision Diagnostics Market by Type
Chapter 7. Asia Pacific Precision Diagnostics Market by Application
Chapter 8. Asia Pacific Precision Diagnostics Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Siemens Healthineers AG (Siemens AG)
- Thermo Fisher Scientific, Inc.
- Danaher Corporation
- Agilent Technologies, Inc.
- BioMerieux S.A.
- Becton, Dickinson and Company
- Qiagen N.V
- Hologic, Inc.
Methodology
LOADING...
